Fenofibrate and Hepatitis fulminant - a phase IV clinical study of FDA data

Summary:

Hepatitis fulminant is reported as a side effect among people who take Fenofibrate (fenofibrate), especially for people who are male, 60+ old, also take Paracetamol, and have Dyslipidaemia.

The phase IV clinical study analyzes which people have Hepatitis fulminant when taking Fenofibrate. It is created by eHealthMe based on reports of 39,402 people who have side effects when taking Fenofibrate from the FDA, and is updated regularly.

What is Fenofibrate?

Fenofibrate has active ingredients of fenofibrate. It is often used in high blood cholesterol. eHealthMe is studying from 40,457 Fenofibrate users. Check the latest studies of Fenofibrate.

What is Hepatitis fulminant?

Hepatitis fulminant (life-threatening condition defined by significantly impaired liver function) is found to be associated with 450 drugs and 677 conditions by eHealthMe. Check the latest studies of Hepatitis fulminant.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 24, 2026

39,402 people reported to have side effects when taking Fenofibrate.
Among them, 29 people (0.07%) have Hepatitis fulminant.

Could Fenofibrate cause Hepatitis fulminant?

Among these 29 people:

What is the gender of people who have Hepatitis fulminant when taking Fenofibrate? *

female: 42.86 %
male: 57.14 %

What is the age of people who have Hepatitis fulminant when taking Fenofibrate? *

What are other drugs people take besides Fenofibrate? *

What are other side effects people have besides Hepatitis fulminant? *

Alanine Aminotransferase Increased: 5 people, 17.24%
Ascites (accumulation of fluid in the abdominal cavity): 5 people, 17.24%
Aspartate Aminotransferase Increased: 5 people, 17.24%
Bleeding Disorders: 5 people, 17.24%
Blood Bilirubin Increased: 5 people, 17.24%
Hepatorenal Syndrome (renal failure in patients with advanced chronic liver disease): 5 people, 17.24%
Hypotension (abnormally low blood pressure): 2 people, 6.90%
Hepatic Failure (liver failure): 2 people, 6.90%
Brain Contusion (a form of traumatic brain injury): 2 people, 6.90%
Drowsiness: 2 people, 6.90%

What are the existing conditions these people have? *

Dyslipidaemia (abnormal amount of lipids): 12 people, 41.38%
Pain: 11 people, 37.93%
Cardiac Failure: 11 people, 37.93%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 6 people, 20.69%
Sepsis (a severe blood infection that can lead to organ failure and death): 5 people, 17.24%
Osteomyelitis (infection of bone): 2 people, 6.90%
Infection: 2 people, 6.90%
Ill-Defined Disorder: 2 people, 6.90%
High Blood Pressure: 2 people, 6.90%
Urinary Incontinence (inability to control the flow of urine and involuntary urination): 1 person, 3.45%

* Approximation only. Some reports may have incomplete information.

Do you take Fenofibrate and have Hepatitis fulminant?

- Check whether Hepatitis fulminant is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Fenofibrate:

Fenofibrate (40,457 reports)

Browse all side effects of Fenofibrate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hepatitis fulminant:

Hepatitis fulminant (450 drugs)

Browse all the conditions that are associated with Hepatitis fulminant:

Hepatitis fulminant (677 conditions)

Related publications that referenced our studies

Gupta MC, Khanna J, Mathur R, Mittal N, "Lamotrigine-induced fulminant hepatic failure: an unusual presentation", IMSEAR, 2015 Jan .
Gupta MC, Khanna J, Mathur R, Mittal N, "Lamotrigine-induced fulminant hepatic failure: an unusual presentation", IMSEAR, 2015 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on fenofibrate (the active ingredients of Fenofibrate) and Fenofibrate (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.